BEAM
Price
$18.24
Change
+$0.83 (+4.77%)
Updated
May 12 closing price
Capitalization
1.75B
91 days until earnings call
PRME
Price
$1.34
Change
+$0.04 (+3.08%)
Updated
May 12 closing price
Capitalization
175.93M
85 days until earnings call
Ad is loading...

BEAM vs PRME

Header iconBEAM vs PRME Comparison
Open Charts BEAM vs PRMEBanner chart's image
Beam Therapeutics
Price$18.24
Change+$0.83 (+4.77%)
Volume$2.23M
Capitalization1.75B
Prime Medicine
Price$1.34
Change+$0.04 (+3.08%)
Volume$1.58M
Capitalization175.93M
BEAM vs PRME Comparison Chart
Loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BEAM vs. PRME commentary
May 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a StrongBuy and PRME is a Hold.

Ad is loading...
COMPARISON
Comparison
May 13, 2025
Stock price -- (BEAM: $18.24 vs. PRME: $1.34)
Brand notoriety: BEAM and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 79% vs. PRME: 97%
Market capitalization -- BEAM: $1.75B vs. PRME: $175.93M
BEAM [@Biotechnology] is valued at $1.75B. PRME’s [@Biotechnology] market capitalization is $175.93M. The market cap for tickers in the [@Biotechnology] industry ranges from $296.96B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 0 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • BEAM’s FA Score: 0 green, 5 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, both BEAM and PRME are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 5 TA indicator(s) are bullish while PRME’s TA Score has 2 bullish TA indicator(s).

  • BEAM’s TA Score: 5 bullish, 2 bearish.
  • PRME’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, BEAM is a better buy in the short-term than PRME.

Price Growth

BEAM (@Biotechnology) experienced а -7.97% price change this week, while PRME (@Biotechnology) price change was -14.65% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.48%. For the same industry, the average monthly price growth was +10.12%, and the average quarterly price growth was -9.68%.

Reported Earning Dates

BEAM is expected to report earnings on Aug 12, 2025.

PRME is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (-3.48% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($1.75B) has a higher market cap than PRME($176M). BEAM YTD gains are higher at: -26.452 vs. PRME (-54.110). PRME has higher annual earnings (EBITDA): -200M vs. BEAM (-399.03M). BEAM has more cash in the bank: 1.22B vs. PRME (144M). PRME has less debt than BEAM: PRME (121M) vs BEAM (158M). BEAM has higher revenues than PRME: BEAM (63.6M) vs PRME (3.85M).
BEAMPRMEBEAM / PRME
Capitalization1.75B176M995%
EBITDA-399.03M-200M200%
Gain YTD-26.452-54.11049%
P/E RatioN/AN/A-
Revenue63.6M3.85M1,654%
Total Cash1.22B144M847%
Total Debt158M121M131%
FUNDAMENTALS RATINGS
PRME: Fundamental Ratings
PRME
OUTLOOK RATING
1..100
67
VALUATION
overvalued / fair valued / undervalued
1..100
40
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
65
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
58

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BEAMPRME
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
76%
Momentum
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
89%
MACD
ODDS (%)
Bullish Trend 1 day ago
72%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
73%
Advances
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 13 days ago
77%
Declines
ODDS (%)
Bearish Trend 8 days ago
85%
Bearish Trend 5 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
68%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
84%
View a ticker or compare two or three
Ad is loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MNHIX25.08N/A
N/A
Manning & Napier Pro-Blend Max Term I
FDTTX22.63N/A
N/A
Fidelity Advisor Capital Development A
NELCX49.11N/A
N/A
Nuveen Equity Long/Short C
STREX21.38N/A
N/A
Sterling Capital Equity Income R6
PETZX14.02N/A
N/A
Gabelli Pet Parents'™

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
+3.08%
CRSP - PRME
65%
Loosely correlated
+5.53%
BEAM - PRME
60%
Loosely correlated
+4.77%
RXRX - PRME
59%
Loosely correlated
+7.16%
NTLA - PRME
56%
Loosely correlated
+5.30%
CCCC - PRME
54%
Loosely correlated
+7.48%
More